{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "RAPP",
  "company": "Rapport Therapeutics",
  "url": "https://www.orionbiotechai.com/company/RAPP",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "RAPP-BM-P2",
      "program": "RAP-219 / bipolar mania Phase 2 · Topline results",
      "eventLabel": "Clinical results disclosure",
      "status": "Timing changed",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-timing-changed",
      "firstStated": {
        "statement": "topline results expected in the first half of 2027",
        "window": "in the first half of 2027",
        "documentType": "SEC 8-K, Exhibit 99.1",
        "date": "2025-03-11",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-ex99_1.htm"
      },
      "restatements": [
        {
          "kind": "Wording changed",
          "statement": "topline results are now expected in the fourth quarter of 2026",
          "window": "in the fourth quarter of 2026",
          "documentType": "SEC 8-K, Exhibit 99.1",
          "date": "2026-05-07",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm"
        },
        {
          "kind": "Wording changed",
          "statement": "topline results expected in October 2026",
          "window": "in October 2026",
          "documentType": "SEC 8-K, Exhibit 99.1",
          "date": "2026-08-05",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm"
        },
        {
          "kind": "Wording changed",
          "statement": "topline results are expected in October 2026",
          "window": "in October 2026",
          "documentType": "SEC Form 10-Q",
          "date": "2026-08-05",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm"
        }
      ],
      "disclosure": null,
      "additionalDisclosures": [],
      "scopeNotes": [
        "March 11, 2025 is the earliest date in these four founder-reviewed sources. Earlier RAPP statements in the wider research inventory have not been imported as founder-reviewed records.",
        "The two August 5, 2026 documents are shown separately. Each is compared with the preceding checked date, not with the other document from August 5.",
        "The 2025-03-11 source labels the trial Phase 2a; the later selected sources use Phase 2. The founder confirmed the common bipolar-mania topline event in these four sources."
      ],
      "scopeSources": [],
      "contextDisclosures": [
        {
          "kind": "Context disclosed",
          "documentType": "SEC 8-K, Exhibit 99.1",
          "date": "2026-05-07",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm",
          "eventDate": null,
          "eventLabel": null,
          "sourceLocator": "Exhibit 99.1: Bipolar Mania Phase 2 Trial Topline Results section; sentence beginning Enrollment in the Phase 2 trial",
          "excerpts": [
            "Enrollment in the Phase 2 trial is progressing well and topline results are now expected in the fourth quarter of 2026, ahead of the previous guidance of first half of 2027."
          ]
        }
      ],
      "companyReleases": [
        {
          "date": "2025-03-11",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-ex99_1.htm"
        },
        {
          "date": "2026-05-07",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm"
        },
        {
          "date": "2026-08-05",
          "url": "https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm"
        }
      ],
      "secCheckedThrough": "2026-10-12",
      "secScope": "The founder compared four selected SEC sources on 2026-10-12: the 2025-03-11, 2026-05-07 and 2026-08-05 Exhibit 99.1 statements and the 2026-08-05 Form 10-Q statement. RAPP's SEC filing list was checked through 2026-10-12: after 2026-08-05 it lists Forms 4, 144 and SC 13G/A and no other filings; none of these reports trial results.",
      "companyPrCheckedDate": "2026-10-12",
      "companyPrScope": "The company press-release statements checked are the ones preserved as SEC Exhibit 99.1 in the four reviewed sources. The issuer website archive was not checked.",
      "founderCheckedDate": "2026-10-12",
      "rowsShown": 1,
      "rowsTotal": 4,
      "citation": "Rapport Therapeutics (RAPP) — RAP-219 / bipolar mania Phase 2 · Topline results: “in the first half of 2027” (SEC 8-K, Exhibit 99.1 2025-03-11); wording changed from “in the first half of 2027” (2025-03-11) to “in the fourth quarter of 2026” (2026-05-07); wording changed from “in the fourth quarter of 2026” (2026-05-07) to “in October 2026” (2026-08-05); wording changed from “in the fourth quarter of 2026” (2026-05-07) to “in October 2026” (2026-08-05). Status Timing changed, checked 2026-10-12. Sources: https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm",
      "corrections": []
    }
  ]
}